Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria
Florian Kurth
, Tilman Lingscheid, Florian Steiner, Miriam S. Stegemann, Sabine Bélard, Nikolai Menner, Peter Pongratz, Johanna Kim, Horst von Bernuth, Beate Mayer, Georg Damm, Daniel Seehofer, Abdulgabar Salama, Norbert Suttorp, and Thomas Zoller
Author affiliations: Charité–Universitätsmedizin Berlin, Berlin, Germany (F. Kurth, T. Lingscheid, F. Steiner, M.S. Stegemann, S. Bélard, N. Menner, P. Pongratz, J. Kim, H. von Bernuth, B. Mayer, G. Damm, D. Seehofer, A. Salama, N. Suttorp, T. Zoller); Swiss Tropical and Public Health Institute, Basel, Switzerland (T. Zoller)
Main Article
Figure 1
Figure 1. Changes in hemoglobin levels (ΔHb) for patients with and without posttreatment hemolysis after treatment with oral artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria. A) Day (d) 0 to d 14 (overall); B) d 0 to d 3 (treatment period); C) d 3 to d 14 (posttreatment period). Horizontal lines indicate median values, boxes indicate interquartile ranges, whiskers indicate ranges, and solid squares and circles indicate individual patient data points. The Mann-Whitney U test was used for comparative analysis. *p<0.05; †p<0.01; NS, not significant.
Main Article
Page created: July 15, 2016
Page updated: July 15, 2016
Page reviewed: July 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.